Holen Sie sich die Stockscreener-App
34.75
2.86%
0.965
Handel nachbörslich:
34.75
Schlusskurs vom Vortag:
$33.78
Offen:
$34.24
24-Stunden-Volumen:
1.56M
Relative Volume:
1.47
Marktkapitalisierung:
$2.07B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.95M
KGV:
-17.27
EPS:
-2.0123
Netto-Cashflow:
$-95.28M
1W Leistung:
-5.29%
1M Leistung:
+0.43%
6M Leistung:
+121.62%
1J Leistung:
+237.38%
1-Tages-Spanne:
$33.99
$35.45
1-Wochen-Bereich:
$33.30
$38.63
52-Wochen-Spanne:
$8.75
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
34.75 | 2.09B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Guggenheim | Buy |
| 2026-04-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Tyra Biosciences faces earnings test ahead of key trial data By Investing.com - Investing.com Canada
Tyra Biosciences faces earnings test ahead of key trial data - Investing.com UK
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Guggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN
Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility? - Sahm
Guggenheim Securities Issues Buy Rating for Tyra Biosciences - HarianBasis.co
Canaan reports 750,000 shares in Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib - Yahoo Finance
Understanding the Setup: (TYRA) and Scalable Risk - Stock Traders Daily
Top 10 AI-Powered Biotech Stocks to Buy Right Now - Insider Monkey
Tyra Biosciences (TYRA) Stock: Entry Strategy Overview | Q4 2025: EPS Misses EstimatesCommunity Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
44,400 Tyra Biosciences (TYRA) stock options granted to director Dable - Stock Titan
Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership - Stock Titan
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors - marketscreener.com
Tyra Biosciences adds Habib Dable to board of directors By Investing.com - Investing.com India
Yuliya Rueb Net Worth (2026) - GuruFocus
Tyra Biosciences, Inc. ($TYRA) CEO 2025 Pay Revealed - Quiver Quantitative
Cantor Fitzgerald reiterates Tyra Biosciences stock rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tyra Biosciences stock rating - Investing.com
Tyra Biosciences appoints Habib J. Dable to board of directors By Investing.com - Investing.com Australia
Tyra Biosciences appoints Habib J. Dable to board of directors - Investing.com
Tyra Bioscience Expands Board, Appoints New Independent Director - TipRanks
Tyra Biosciences adds Habib Dable to board of directors - Investing.com
[ARS] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences (TYRA) details 2026 virtual meeting, director votes and auditor - Stock Titan
Ty appoints Habib J. Dable to Board as Class II director - TradingView
Habib Dable joins Tyra Biosciences (NASDAQ: TYRA) board as Class II director - Stock Titan
Tyra Biosciences, Inc. (TYRA) Stock Analysis: Unveiling a 45.89% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch - TipRanks
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Guggenheim - MarketBeat
TYRA Initiates Coverage On by Guggenheim -- Price Target Announced at $54.00 - GuruFocus
This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Guggenheim Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛
Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target - marketscreener.com
Guggenheim Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $54 - 富途牛牛
TYRA (Nasdaq) Form 144: Director reports two 8,000-share transactions - Stock Titan
The Technical Signals Behind (TYRA) That Institutions Follow - Stock Traders Daily
Growth Stocks To Watch Today – April 10th - Defense World
JPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRA - MarketBeat
IPO Launch: Is Tyra Biosciences Incs ROE strong enoughEntry Point & Precise Swing Trade Alerts - baoquankhu1.vn
FMR LLC holds 14.4% of Tyra Biosciences (NASDAQ: TYRA) - Stock Titan
Tyra Biosciences (NASDAQ:TYRA) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
CCORF Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $50 - 富途牛牛
Is Tyra Biosciences (TYRA) Stock a Good Buy in 2026 | Price at $38.93, Down 1.72%Investment Signal Network - Xã Thanh Hà
Growth Stocks To Watch Now – April 3rd - Defense World
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tyra Biosciences Inc-Aktie (TYRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KAPLAN GILLA | Director |
Mar 25 '26 |
Option Exercise |
2.25 |
14,295 |
32,164 |
42,526 |
| KAPLAN GILLA | Director |
Mar 25 '26 |
Sale |
36.97 |
14,295 |
528,506 |
28,231 |
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):